Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Bladder cancer (BC), the second most common urological malignancy, is an important public
health issue. One of the main challenges in the treatment of bladder cancer if the prevention
of recurrences of non-invasive tumors, which is also associated with significant costs.
The current study will investigate optimal treatment of patients with bladder cancer with
high risk of tumor recurrence but low risk of progression. The main interest is comparison of
photodynamic (PDD) bladder tumor resection (TUR-BR)to traditional TUR-BT. Also the efficacy
of adjuvant optimized mitomycin-C is compared to patients with no adjuvant treatment.